Vaccine & Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America ; Department of Applied Mathematics, University of Washington, Seattle, Washington, United States of America.
PLoS One. 2013 Sep 16;8(9):e73770. doi: 10.1371/journal.pone.0073770. eCollection 2013.
HIV prevalence among pregnant women in Southern Africa is extremely high. Epidemiological studies suggest that pregnancy increases the risk of HIV sexual acquisition and that HIV infections acquired during pregnancy carry higher risk of mother-to-child transmission (MTCT). We analyze the potential benefits from extending the availability of effective microbicide to pregnant women (in addition to non-pregnant women) in a wide-scale intervention.
A transmission dynamic model was designed to assess the impact of microbicide use in high HIV prevalence settings and to estimate proportions of new HIV infections, infections acquired during pregnancy, and MTCT prevented over 10 years. Our analysis suggests that consistent use of microbicide with 70% efficacy by 60% of non-pregnant women may prevent approximately 40% and 15% of new infections in women and men respectively over 10 years, assuming no additional increase in HIV risk to either partner during pregnancy (RR(HIV/preg) = 1). It may also prevent 8-15% MTCT depending on the increase in MTCT risk when HIV is acquired during pregnancy compared to before pregnancy (RRMTCT/preg). Extending the microbicides use during pregnancy may improve the effectiveness of the intervention by 10% (RR(HIV/preg) = 1) to 25% (RR(HIV/preg) = 2) and reduce the number of HIV infections acquired during pregnancy by 40% to 70% in different scenarios. It may add between 6% (RR(HIV/preg) = 1, RR(MTCT/preg) = 1) and 25% (RR(HIV/preg) = 2, RR(MTCT/preg) = 4) to the reduction in the residual MTCT.
Providing safe and effective microbicide to pregnant women in the context of wide-scale interventions would be desirable as it would increase the effectiveness of the intervention and significantly reduce the number of HIV infections acquired during pregnancy. The projected benefits from covering pregnant women by the HIV prevention programs is more substantial in communities in which the sexual risk during pregnancy is elevated.
在南部非洲,孕妇中的 HIV 流行率极高。流行病学研究表明,怀孕会增加 HIV 性传播的风险,而怀孕期间感染 HIV 会增加母婴传播(MTCT)的风险。我们分析了在广泛干预措施中为孕妇(除非孕妇外)提供有效的杀微生物剂的潜在益处。
设计了一种传播动力学模型,以评估在 HIV 高流行率环境中使用杀微生物剂的影响,并估计在 10 年内新的 HIV 感染、怀孕期间获得的感染以及预防母婴传播的比例。我们的分析表明,假设在怀孕期间,任何一方的 HIV 风险都不会增加(RR(HIV/preg)= 1),那么 60%的非孕妇持续使用 70%有效率的杀微生物剂,可能会在 10 年内分别预防女性和男性中约 40%和 15%的新感染。此外,根据怀孕期间获得 HIV 与怀孕前相比 MTCT 风险的增加情况,杀微生物剂的使用也可能预防 8-15%的 MTCT。在不同情况下,将杀微生物剂的使用扩展到怀孕期间可能会使干预措施的有效性提高 10%(RR(HIV/preg)= 1)至 25%(RR(HIV/preg)= 2),并减少 40%至 70%的怀孕期间获得的 HIV 感染。在 RR(HIV/preg)= 1,RR(MTCT/preg)= 1 的情况下,它可能会使剩余 MTCT 减少 6%,在 RR(HIV/preg)= 2,RR(MTCT/preg)= 4 的情况下,它可能会使剩余 MTCT 减少 25%。
在广泛的干预措施中为孕妇提供安全有效的杀微生物剂是可取的,因为它会增加干预措施的有效性,并显著减少怀孕期间获得的 HIV 感染数量。在怀孕期间性风险升高的社区中,通过 HIV 预防计划覆盖孕妇所带来的预期收益更为可观。